Is the Ovid Therapeutics (OVID) investment thesis intact?

Yes. Readouts currently rates the Ovid Therapeutics Thesis Intact. OV329's Phase 2 is underway; a photosensitivity readout near year-end 2026 comes first.

What is the next catalyst for Ovid Therapeutics (OVID)?

The next dated event is Trial start for OV329, expected Q4 2026, as stated by the company. Also ahead: Trial start for OV4071, expected H2 2026.

How long will Ovid Therapeutics' cash last?

Ovid Therapeutics has said its cash will fund operations into 2029 (guidance as of August 13, 2026).

OVIDOvid Therapeutics Inc.

Market reactionShares rose 14% on Nov 4.

IntactLast material event Aug 13, 2026 · Updated Oct 12, 2026

OV329's Phase 2 is underway; a photosensitivity readout near year-end 2026 comes first

Ovid Therapeutics is a clinical-stage company developing OV329, an oral drug for seizures that resist existing treatments, and OV4071 for schizophrenia; neither is approved.

Ovid's case rests on OV329, an oral GABA aminotransferase inhibitor, the mechanism of the approved drug vigabatrin. In healthy volunteers OV329 matched or exceeded vigabatrin's effect on brain inhibition with no eye or retinal changes. A placebo-controlled Phase 2 in treatment-resistant focal seizures started in 2026 and is due to finish in H2 2027; a photosensitivity study reports near year-end 2026. OV4071, a KCC2 activator for schizophrenia, is in Phase 1. Cash of $169.8 million is guided to last into 2029.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

OV329 shows anti-seizure activity in the photosensitivity studyAwaiting evidencePhotosensitivity study results.Next: Photosensitivity study results.

Why it is in this state

The evidence, what would weaken it and the source filing

OV329 reduces focal seizures versus placeboAwaiting evidencePhase 2 results after completion in H2 2027.Next: Phase 2 results after completion in H2 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

OV329 avoids vigabatrin-type eye toxicitySupportedEye safety data from the Phase 2 trials.Next: Eye safety data from the Phase 2 trials.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts past the Phase 2 resultsSupportedThe Q3 cash update.Next: The Q3 cash update.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Photosensitivity study results

Tests: OV329 shows anti-seizure activity in the photosensitivity study

Near year-end 2026 (company guidance)

Does OV329 show anti-seizure activity in the photosensitivity study?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical

+6.9%Aug 13, 2026

OV329's Phase 2 is underway; a photosensitivity readout near year-end 2026 comes first

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Treatment-resistant focal onset seizures

OV329 · 1 upcoming

Phase 2 Data

H2 2027

Psychosis· proof-of-mechanism

OV4071 · 1 upcoming

Study Initiation

H2 2026

Tuberous sclerosis complex-associated seizures

OV329 · 1 upcoming

Study Initiation

Q4 2026

Photosensitive epilepsy· proof of mechanism

OV329 · 1 upcoming

Data

Year-end 2026

Acute schizophrenia

OV4071 · 1 upcoming

Phase 2 Study Initiation

2027

Infantile spasms

OV329 · 1 upcoming

Study Initiation

2027

Psychosis in neuronal-synuclein diseases

OV4071 · 2 completed

Phase 1 Study Initiation

Reported May 12, 2026

Regulatory Decision

Reported Mar 18, 2026

Treatment-resistant focal seizures

OV329 · 1 completed

Phase 2a Study Initiation

Apr 1, 2026

Epilepsy, psychosis

OV350 · 1 completed

Phase 1 Data

Reported Dec 18, 2025

Drug-resistant epilepsy

OV329 · 1 completed

Phase 1 Data

Reported Oct 3, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Ovid Therapeutics (OVID) investment thesis intact?: Yes. Readouts currently rates the Ovid Therapeutics Thesis Intact. OV329's Phase 2 is underway; a photosensitivity readout near year-end 2026 comes first.
What is the next catalyst for Ovid Therapeutics (OVID)?: The next dated event is Trial start for OV329, expected Q4 2026, as stated by the company. Also ahead: Trial start for OV4071, expected H2 2026.
How long will Ovid Therapeutics' cash last?: Ovid Therapeutics has said its cash will fund operations into 2029 (guidance as of August 13, 2026).

Other companies we cover in these diseases

Photosensitive epilepsy: Biohaven (BHVN)
Schizophrenia: Anavex Life Sciences (AVXL)NRx Pharmaceuticals (NRXP)

Disease areas: Neurology and pain, Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

9 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.